QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-pepgen-shares-are-trading-higher-by-112-here-are-20-stocks-moving-premarket

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritt...

 zevra-therapeutics-presents-several-posters-highlighting-new-data-on-miplyffa-for-treatment-of-niemann-pick-disease-type-c-at-iciem

New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced ...

 zevra-therapeutics-to-present-four-posters-on-miplyffa-at-iciem-2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for p...

 jmp-securities-maintains-market-outperform-on-zevra-therapeutics-lowers-price-target-to-18

JMP Securities analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and lowers the pr...

 zevra-therapeutics-q2-eps-124-beats-113-estimate-sales-2590m-beat-2249m-estimate

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1...

 zevra-therapeutics-has-submitted-a-marketing-authorization-application-to-the-european-medicines-agency-for-the-evaluation-of-arimoclomol-for-niemann-pick-disease-type-c

The EMA will review the application under the centralized marketing authorization procedure. If a marketing authorization is gr...

 zevra-therapeutics-to-present-three-posters-on-miplyffa-and-one-on-olpruva-annual-sergg-2025

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for p...

 cantor-fitzgerald-maintains-overweight-on-zevra-therapeutics-raises-price-target-to-29

Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight and raises the price t...

 how-zevras-miplyffa-could-transform-investment-strategies

HC Wainwright sees Zevra's Miplyffa launch and EU plans driving upside, initiating coverage with a $26 target and Buy ratin...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION